Clairity founder Connie Lehman, MD, PhD, will serve a new role as the company's CEO. Clairity also named Joe Kiani as chair of its board of directors.
The appointments follow Clairity receiving de novo authorization from the U.S. Food and Drug Administration (FDA) for the company's mammography-based AI risk prediction platform, Clairity Breast. The company is actively engaging with public- and private-sector stakeholders for its technologies, it said.
This announcement also follows the closing of a $43 million funding round that the firm will use for technology commercialization and development.
As CEO, Lehman will lead company strategy, operations, and partnerships as Clairity integrates across a global and diverse range of clinical environments.
Lehman is a professor of radiology at Harvard Medical School and a breast imaging specialist at Mass General Brigham, where she is currently on leave. She has authored more than 300 peer-reviewed scientific publications and has led pioneering work in computer-aided diagnosis, deep learning, breast density assessment, and predictive risk modeling.
Lehman earned her medical degree and doctorate from Yale University after graduating Phi Beta Kappa from Duke University.
